A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
This phase II clinical trial studies the safety and effect of Gimatecan in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or peritoneal cancer.

The chemotherapy will be given every four weeks.This study is a single-arm, multi-center research design.
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer
DRUG: Gimatecan
Objective response rate (ORR), Percentage of patients with objective response assessed by best overall response (BOR) and independent review committee （IRC） of either complete response(CR) or partial remission(PR) will be reported., To evaluate objective response rate every 8 weeks after the initiation of chemotherapy, up to 24 months.
Progression free survival (PFS), The 2-year progression free survival of the whole group., From date of randomization until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 24 months.|Disease control rate (DCR), will be reported., To evaluate disease control rate every 8 weeks after the initiation of chemotherapy, up to 24 months.|Duration of Response (DoR), The 2-year overall survival of the whole group., From date of randomization until the date of death from any cause or the date of last follow-up whichever came first, assessed up to 24 months.|Overall survival (OS), The 2-year overall survival of the whole group., From date of randomization until the date of death from any cause or the date of last follow-up whichever came first, assessed up to 24 months.
The study had 3 phases: screening phase, treatment phase and follow-up phase. During the treatment phase, the drug will continue to be administered until the progression of disease, complete remission , unacceptable toxicity.